Trademark: 97697528
Word
CELLERITAS
Status
Pending
Status Code
730
Status Date
Thursday, May 9, 2024
Serial Number
97697528
Mark Type
4
Filing Date
Wednesday, November 30, 2022
Published for Opposition
Tuesday, October 17, 2023

Trademark Owner History

Classifications
40 Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
42 Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy

Trademark Events
Dec 3, 2022
New Application Entered
Dec 22, 2022
New Application Office Supplied Data Entered
Sep 9, 2023
Assigned To Examiner
Sep 14, 2023
Approved For Pub - Principal Register
Sep 27, 2023
Notification Of Notice Of Publication E-Mailed
Oct 17, 2023
Published For Opposition
Oct 17, 2023
Official Gazette Publication Confirmation E-Mailed
May 9, 2024
Sou Extension 1 Granted
May 9, 2024
Sou Teas Extension Received
May 9, 2024
Sou Extension 1 Filed
May 10, 2024
Notice Of Approval Of Extension Request E-Mailed
Dec 12, 2023
Noa E-Mailed - Sou Required From Applicant

Trademark Alertz updated from USPTO on 2030-01-24